BERLIN (Reuters) – Pfizer said on Thursday it had submitted an application to Swissmedic for authorisation of a further bivalent COVID-19 vaccine.
The ready-to-use dispersion for injection contained both messenger RNA (mRNA) from the original Pfizer/BioNTech COVID-19 vaccine and mRNA coding for the spike protein of Omicron variants BA.4 and BA.5, Pfizer said.
(Reporting by Kirsti Knolle; Editing by Paul Carrel)
